McKesson Stock News

The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Dividend Aristocrats offer a better alternative to the traditional 60-40 portfolio and S&P. These 12 Aristocrats provide a 3.2% yield, 14% discount, 22% upside potential next year, and 10% long-term inc...

Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciations have contributed 68%.

McKesson Corporation (NYSE:MCK ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 8:20 AM ET Company Participants Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Elizabeth Anderson Thank you for joining us this morning. Appreciate you coming by.

CNBC's Jim Cramer listed ten stocks he thinks will do well in December. Cramer said winners from November usually continue to perform during the last month of the year.

I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven ...

McKesson's earnings for its fiscal 2025 second quarter exceeded expectations, despite special charges that cut into net income.

McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript

Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S. pharmaceuticals segment on robust demand for specialty and branded drugs.